Journal
ANTICANCER RESEARCH
Volume 39, Issue 12, Pages 6463-6470Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.13860
Keywords
Colorectal cancer; trabectedin; irinotecan; leucovorin; 5-fluorouracil; FOLFIRI; PDOX; combination therapy
Categories
Funding
- National Natural Science Foundation of China [81702424, 81872364]
- Joint Funds for the Innovation of Science and Technology, Fujian Province [2017Y9092]
- Fujian Provincial Health Department Young and Middle-aged Talents Training Project [2018-ZQN-46]
- Project of Science and Technology Research Program in Fujian Province [2016B044]
- Fujian Provincial Natural Science Foundation [2018J05127]
- National Clinical Key Specialty Construction Project (General Surgery) of China
Ask authors/readers for more resources
Background/Aim: The aim of the present study was to determine the efficacy of trabectedin combined with FOLFIRI (irinotecan, leucovorin and 5-fluorouracil) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (iPDOX) mouse model. Materials and Methods: A CRC tumor from a patient previously established in nude mice was implanted subcutaneously in transgenic green fluorescence protein (GFP)-expressing nude mice in order to label the tumor stromal cells with GFP. Mice were randomized into four groups: Group 1, untreated control; group 2, FOLFIRI; group 3, trabectedin alone; group 4, trabectedin plus FOLFIRI. Tumor width, length, and mouse body weight was measured twice every week. Results: All three treatment groups showed inhibited tumor growth compared to the untreated control group. Only the combination of FOLFIRI and trabectedin arrested tumor growth. No significant changes was observed in body weight in any group. Conclusion: These findings suggest that the combination of trabectedin plus FOLFIRI has clinical potential for patients with CRC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available